Glaxo Hit With Another Zofran Birth Defect Claim
GlaxoSmithKline has been named in another Zofran lawsuit over the drug’s alleged connection to birth defects. This latest case, which is now pending in U.S. District Court, Northern District of Alabama, was filed on behalf of a boy who was born with a chromosomal abnormality after his mother used Zofran to control nausea and vomiting during the first trimester of pregnancy.
According to the April 1st complaint, the now 8-year-old boy was born in August 2006, and has since been diagnosed with myriad health issues, including extra digits, distended kidney, glaucoma, a seizure disorder, and a urethral disorder. He was ultimately found to be suffering from a defect involving the duplication of the long arm of his 13th chromosome. Testing conducted by a geneticist confirmed that neither of the boy’s parents suffered from any chromosomal issues that could have been passed on to their baby.
The lawsuit points out that the boy’s health issues are expected to continue throughout his life. In addition, he is a special needs child who is nonverbal and has delayed reactions. The Zofran lawsuit filed on his behalf by his mother seeks compensatory damages for medical expenses, pain and suffering and other damages associated with his medical problems.
Zofran Litigation Continues to Grow
A number of similar Zofran birth defect claims have been filed in other U.S. jurisdictions since January, including cases pending in Massachusetts and Pennsylvania federal court that allege Zofran caused babies to be born with serious heart birth defects. A third claim pending in California state court blames the anti-nausea medication for a cardiac problem suffered by a baby from that state.
It should be noted that Zofran has never been approved to treat pregnancy-related nausea and vomiting, as it has not been well studied in pregnant women. This is also not the first time Glaxo has faced legal action over the medication. In 2012, the company reached a $3 billion settlement with the U.S. Department of Justice to resolve charges that it had improperly marketed Zofran and other drugs for unapproved uses. Among other things, the Glaxo was accused of marketing the anti-nausea drug as a treatment for morning sickness.
Children who were allegedly born with Zofran birth defects may be entitled to compensation from Glaxo. If you would like to learn more about the litigation involving this medication, please contact Bernstein Liebhard LLP by calling 1-877-779-1414 today.